Sun Pharma's Para IV Pipeline Analysis
Sun Pharma has the pipeline of ~29 Para IVs having branded sales of ~$25b. Among its Para IV pipeline the confirmed opportunities (branded sales of ~ $7.8b) are Gleevec, Namenda, Comtan, Stalevo, Temodar, Eloxatin, Clarinex, Vanos, and Lexapro. Among these Gleevec, Stalevo and Eloxatin could be the most lucrative ones. Other than these Para IVs, we believe Nexium IV and Ryzolt have the potential to fetch considerable upside. We expect PAT of ~$557m from Para IVs which is ~ 5% of Sun’s market cap
Sun Pharma has been largely successful in Para IV litigations, with successes like Gemzar, Eloxatin and Prandin. Based on this, we believe Sun Pharma has the potential to throw surprises from its pipeline.
Sun Pharma has been largely successful in Para IV litigations, with successes like Gemzar, Eloxatin and Prandin. Based on this, we believe Sun Pharma has the potential to throw surprises from its pipeline.
COMPANIES MENTIONED
SUN PHARMA, SUNP
SUN PHARMA, SUNP
